Potential Drug Interaction in Patients with Schizophrenia
DOI:
https://doi.org/10.53089/medula.v14i8.1165Keywords:
Antipsikotik, Interaksi Obat, Lexicomp, SkizofreniaAbstract
In the treatment of schizophrenia, antipsychotics as the main therapy are generally combined with additional therapy. Combination therapy has a risk of drug interactions. The aim of the study was to describe the potential factors that influence drug interactions. The study was conducted using observational quantitative analytic methods with a retrospective cross-sectional approach. The sample was selected by total sampling method in the medical records of inpatients at the Lampung Mental Hospital from January-December 2022. The Lexicomp software was used to identify potential drug interactions. In the 265 samples, 344 treatment profiles were obtained with a total of 1349 drugs used. Then, 1786 potential drug interactions were classified as level of risk A (0%), B (0.8%), C (80.2%), D (19%), and X (0%). There was a significant relationship between gender, length of stay, and number of drugs (p<0.05) on potential drug interaction level D (major). Multivariate analysis showed the number of drugs had the strongest relationship (p=0.000 OR=8.233) to potential drug interactions. There was a significant relationship between gender, length of stay, and number of drugs with potential drug interactions level D. The number of drugs had the strongest with potential drug interactions.
References
WHO. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHO Version [Internet]. 2016 [cited 2022 Sep 23]. Available from: https://icd.who.int/browse10/2016/en#/F20-F29
Wells BG, DiPiro JT, Schwinghammer TL, DiPiro C V. Pharmacotherapy Handbook. Ninth Edition. McGraw-Hill Education; 2015. 731–746 p.
DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V. Pharmacotheraphy: A Pathophysiologic Approach. Eleventh Edition. McGraw Hill; 2020. 84–85 p.
Lähteenvuo M, Tiihonen J. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. Vol. 81, Drugs. Adis; 2021. p. 1273–84.
Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean medication algorithm for schizophrenia 2019, second revision: Treatment of psychotic symptoms. Clinical Psychopharmacology and Neuroscience. 2020 May 1;18(3):386–94.
García J, Vaz M, Poggi M. Estimated Prevalence of Contraindicated, Severe and Moderate Interactions In Ambulatory Patients With Polypharmacy In A Healthcare Provider In Uruguay. Clin Ther. 2015 Aug;37(8):e145.
Mcmahon CG, Cahir CA, Kenny RA, Bennett K. Inappropriate prescribing in older fallers presenting to an Irish emergency department. Age Ageing. 2014 Jan;43(1):44–50.
Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. Vol. 27, CNS Drugs. 2013. p. 1021–48.
WHO. Medication Safety in Polypharmacy [Internet]. Switzerland: Medication Without Harm; 2019. 11–15 p. Available from: http://apps.who.int/bookorders.
Baxter Karen, Stockley IH. Stokcley’s Drug Interaction. Ninth Edition. Baxter K, editor. United States of American: Pharmaceutical Press; 2010. 1–833 p.
Bailie GR, Johnson CA, Mason NA, St Peter WL. Medfacts Pocket Guide of Drug Interaction. Second Edition. Middleton: Bone Care International; 2004. 3–51 p.
Janković SM, Pejčić A V., Milosavljević MN, Opančina VD, Pešić N V., Nedeljković TT, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care. 2018 Feb 1;43:1–6.
Zhelyazkova-Savova M, Todorova-Nenova K, Gancheva S, Karadjova D. Evaluation Of Potential Drug-Drug Interactions In Psychiatric Patients: A Pilot Study. Scripta Scientifica Medica. 2018;50(3):34–40.
Utami VW, Darajati M, Puspitasari CE. Potensi interaksi obat pada pasien skizofrenia di Rumah Sakit Jiwa Mutiara Sukma tahun 2020. Sasambo Journal of Pharmacy (SJP) [Internet]. 2022;3(1):36–42. Available from: https://jffk.unram.ac.id/index.php/sjp
Fraga ADSS, Bessy ML. Identifikasi Potensi Interaksi Obat Pada Pasien Skizofrenia di Rumah Sakit Jiwa Naimata Kupang. Jurnal Farmagazine [Internet]. 2022;9(2):40–6. Available from: http://dx.doi.org/10.47653/farm.v9i2.632
Puspitasari AW, Angeline L. Analisis Potensi Interaksi Obat Golongan Antidepresan pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Tahun 2016 Analysis of Potential Antidepressant Drug Interactions in Schizophrenic Patients at Dr. Soeharto Heerdjan 2016. Pharmaceutical Sciences and Research. 2019;6(1):13–20.
Kementerian Kesehatan RI. Laporan Nasional Riset Kesehatan Dasar 2018. Jakarta; 2018. 223–225 p.
Ramdini DA, Sumiwi SA, Barliana MI, Destiani DP, Nur IL. Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat. Indonesian Journal of Clinical Pharmacy. 2018 Dec 29;7(4):280–93.
Todorova-Nenova K, Zhelyazkova-Savova M, Gancheva S, Stoychev E. Potential drug-drug interactions in psychiatric patients during hospitalization and at hospital discharge. Journal of IMAB - Annual Proceeding (Scientific Papers) [Internet]. 2022 Feb 9;28(1):4223–8. Available from: https://www.journal-imab-bg.org/issues-2022/issue1/vol28issue1p4223-4228.html
Tatro DS. Drug Interaction Facts. USA: Wolters Kluwer Health; 2011.
Baxter Karen, Stockley IH. Stockley’s drug interactions. 8th ed. London: Pharmaceutical Press; 2008.
Murri MB, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, et al. Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis. Drugs in R and D. 2015 Mar 14;15(1):45–62.
Steeds H, Carhart-Harris RL, Stone JM. Drug models of schizophrenia. Ther Adv Psychopharmacol. 2015;5(1):43–58.
Luvsannyam E, Jain MS, Pormento MKL, Siddiqui H, Balagtas ARA, Emuze BO, et al. Neurobiology of Schizophrenia: A Comprehensive Review. Cureus. 2022 Apr 8;14(4):1–7.
Saputra DR, Mayasari D, Rusli R. Analisis Interaksi Obat Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap RSJD Atma Husada Mahakam Samarinda Periode Tahun 2019. Mulawarman Pharmaceuticals Conferences [Internet]. 2020;111–6. Available from: https://doi.org/10.25026/mpc.v12i1.430
Novita NF, Destiani DP. INTERKASI OBAT TERHADAP PERPANJANGAN INTERVAL QT. Farmaka. 2020;18(1):110–8.
Aberg, J.A., Lacy, C., Amstrong, L., Goldman, M., and Lance LL. Drug Information Handbook 17th Edition. American Pharmacist Association; 2009.
Setiawati MCN, Munif Yasin N, Laksmi SR, Tinggi Ilmu Farmasi S, Pharmasi Y, jend Sarwo Edie Wibowo Km L, et al. Evaluation of side effect of risperidon on schizophrenic patient in Amino Gondohutomo hospital Semarang. Majalah Farmasi Indonesia. 2010;21(2):2010.
Saharuddin, Ikawati Z, Kristanto CS. Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang. Majalah Farmaseutik. 2021;17(2):206–16.
Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers Introduction Methods. Br J Clin Pharmacol. 1999;48:323–30.
Eugene AR, Eugene B, Masiak M, Masiak JS. Head-to-Head Comparison of Sedation and Somnolence Among 37 Antipsychotics in Schizophrenia, Bipolar Disorder, Major Depression, Autism Spectrum Disorders, Delirium, and Repurposed in COVID-19, Infectious Diseases, and Oncology From the FAERS, 2004–2020. Front Pharmacol. 2021 Mar 25;12.
Suri N, Natari RB, Putri GJ. Polypharmacy and outpatient attendance of people with schizophrenia in Indonesia. Pharmacoepidemiol Drug Saf [Internet]. 2021 Aug 1 [cited 2024 Jan 1];130. Available from:https://pubmed.ncbi.nlm.nih.gov/34431155/
Chen HK, Hsieh CJ. Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study. Schizophr Res. 2018 May 1;195:237–44.
Bačar Bole C, Nagode K, Pišlar M, Mrhar A, Grabnar I, Vovk T. Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. Medicina (Lithuania). 2023 Feb 1;59(2).
Pu C, Huang B, Zhou T, Cheng Z, Wang Y, Shi C, et al. Gender differences in the first-year antipsychotic treatment for chinese first-episode schizophrenia. Neuropsychiatr Dis Treat. 2020;16:3145–52.
Dagnew EM, Ergena AE, Wondm SA, Sendekie AK. Potential drug-drug interactions and associated factors among admitted patients with psychiatric disorders at selected hospitals in Northwest Ethiopia. BMC Pharmacol Toxicol. 2022 Dec 1;23(88):1–9.
Sari DP. Interaksi Obat Antipsikotik Pada Pengobatan Pasien Skizofrenia Rawat Jalan di RSUP H. Adam Malik Medan (Skripsi). Medan: Universitas Sumatera Utara; 2015.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct 10;17(1):1–10.
Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J, et al. Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis. BMC Geriatr. 2022 Dec 1;22(601):1–12.
Aburamadan H, Sridhar S, Tadross T. Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital, United Arab Emirates. J Adv Pharm Technol Res. 2021 Jan 1;12(1):45–51.
Velelekou A, Papathanasiou I V., Alikari V, Papagiannis D, Tsaras K, Fradelos EC. Factors influencing the duration of hospitalization of patients with schizophrenia. Med Pharm Rep. 2022;95(3):290–9.
Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, et al. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging. 2014 Apr 1;31(4):283–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
